Clinical Trials
57 trialsSTARTRK-2
Hoffmann-La Roche
TRIDENT-1
Turning Point Therapeutics, Inc.
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Boehringer Ingelheim
CHRYSALIS
Janssen Research & Development, LLC
MARIPOSA
Janssen Research & Development, LLC
PAPILLON
Janssen Research & Development, LLC
MARIPOSA-2
Janssen Research & Development, LLC
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
LAURA
AstraZeneca
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
NAVIGATE
Bayer
LIBRETTO-001
Eli Lilly and Company
VISION
EMD Serono
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo
PEARLS
Merck Sharp & Dohme LLC
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Takeda
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Nuvation Bio Inc.
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Dizal Pharmaceuticals
RELAY
Eli Lilly and Company
GARNET
Tesaro, Inc.
TRUST-II
Nuvation Bio Inc.
CheckMate 816
Bristol-Myers Squibb
LIBRETTO-121
Eli Lilly and Company
CheckMate 9LA
Bristol-Myers Squibb
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie
CheckMate 227
Bristol-Myers Squibb
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings, Inc.
FLAURA2
AstraZeneca
MK-3475A-D77
Merck Sharp & Dohme LLC
ALEX
Hoffmann-La Roche
AEGEAN
AstraZeneca
ARROW
Hoffmann-La Roche
DESTINY-Lung01
Daiichi Sankyo
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Partner Therapeutics, Inc.
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
MK-3475-671
Merck Sharp & Dohme LLC
KEYNOTE-407
Merck Sharp & Dohme LLC
MK-3475-189
Merck Sharp & Dohme LLC
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
PACIFIC
AstraZeneca